Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer’s Disease Annual Meeting
Globe Newswire•02/11/2026•08:30 ET
0
Key Highlights
- ➤Lantheus will present Alzheimer’s disease imaging data at the 2026 CTAD Annual Meeting
- ➤Florquinitau F 18 PET tau-detection performance comes from pivotal phase 3 studies
- ➤Lantheus will present 18F-FDED PET imaging data on astrocytic MAO-B age dependence
Expert Statements
Christopher Rowe, Director of Molecular Imaging Research at Austin Health
“Detection of tau pathology in patients with early Alzheimer’s disease: Diagnostic performance of florquinitau F 18 PET in pivotal phase 3 studies”
Gerard Nisal Bischof, Director Medical Imaging at Lantheus
“Minimal age dependence of astrocytic MAO-B with 18F-FDED PET Imaging in the Alzheimer’s disease spectrum”
BEDFORD, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced data to be featured at the 2026 Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting, taking place November 16 – November 19, 2026 in Boston, MA.
Date & Time: Monday, November 16 (2:00 p.m. ET) – Tuesday, November 17 (5:30 p.m. ET) Session Type: Poster Session Title: MRI & Imaging
Get started
Create a free account to read the full story.